Alembic Wins FDA Nod for Fingolimod, Targeting $145M MS Market

Alembic Pharmaceuticals has secured USFDA approval for Fingolimod Capsules 0.5 mg, a generic equivalent to Novartis Pharmaceuticals Corporation's branded reference listed drug. The approval positions Alembic to compete in a U.S. market valued at approximately US$ 145 million, adding meaningful commercial weight to the company's CNS generics portfolio and intensifying generic competition in the multiple sclerosis treatment segment.

Fingolimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis. As a branded therapy, it has represented a significant revenue contributor to Novartis's neuroscience franchise. Generic entrants with USFDA approval must demonstrate bioequivalence and comply with applicable 21 CFR Part 211 current Good Manufacturing Practice requirements -- a regulatory bar that, once cleared, enables direct substitution at the pharmacy level and accelerates formulary-level price competition.

For QA and regulatory affairs teams at competing manufacturers, Alembic's approval is a signal worth tracking. Indian generics manufacturers have steadily expanded their share of high-value, complex oral solid dosage markets in the U.S., and CNS categories -- historically dominated by innovator brands -- are increasingly within scope. Supply chain planners at health systems and PBMs will note that an additional approved supplier for a critical MS therapy improves sourcing optionality and reduces single-source dependency risk.

Alembic Pharmaceuticals describes itself as a vertically integrated research and development pharmaceutical entity with a strong presence in the pharmaceutical industry. This approval reflects the company's continued regulatory engagement with the USFDA across its generics pipeline. Source: EIN Presswire / Pharmaceutical Industry News, published 25 April 2026.